Frazier Life Sciences Management, L.P. Alkermes Plc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Alkermes Plc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 576,129 shares of ALKS stock, worth $18 Million. This represents 0.87% of its overall portfolio holdings.
Number of Shares
576,129Holding current value
$18 Million% of portfolio
0.87%Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
358Shares Held
180MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$908 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$592 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$405 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$395 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$286 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.12B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...